Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Oct 2025 According to Merck media release, the pooled data from the trial along with STELLAR and ZENITH trials will be presented at the American Heart Association (AHA) Scientific Sessions 2025.
16 May 2025 According to an Merck Sharp and Dohme media release, company announced data from this trial on pulmonary arterial hypertension (PAH) to be presented at the American Thoracic Societys (ATS) 2025 International Conference in San Francisco from May 16-21.
22 May 2024 Results of this study presented at the 120th International Conference of the American Thoracic Society

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com